ArticleJournal of hematology & oncology2025

BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial.

Hao Yao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.